Brandon Wainwright

Professor Brandon Wainwright AM is Co-Director of the Children’s Brain Cancer Centre and leads a laboratory within the UQ Diamantina Institute focused on understanding the genetic pathways behind medulloblastoma, a type of brain tumour that occurs predominantly in children. He is Chair of the European Molecular Biology Laboratory (EMBL) Australia, Chair of the Advisory Board of the Robinson Research Institute and Chair of the Board of the South Australian Immunogenomics Cancer Institute (SAIGENCI), and serves on the boards the Australian Genome Research Facility as well as several national and international scientific review committees, including the MRFF Brain Tumour Roadmap Committee. Professor Wainwright completed his undergraduate and postgraduate studies at The University of Adelaide, after which he secured a postdoctoral fellowship with St Mary's Hospital at Imperial College London. During his six years at Imperial he worked on the first human genome project and also became a Medical Research Council Senior Research Fellow. He returned to Australia in 1990 to join UQ's Centre for Molecular and Cellular Biology (now IMB) and led the Institute for Molecular Biology until 2019. Professor Wainwright is a geneticist, renowned for discovering the genetic pathway that causes most human cancer. He is skilled in molecular genetics, where he is using genetic approaches to dig through DNA and find the genes that cause disease. He commenced using these skills to locate the cystic fibrosis gene, but it was when isolating a gene responsible for a rare form of brain cancer called Medulloblastoma, that he discovered the role of the ‘Hedgehog Pathway' in common human cancer. Cancer and cell signalling: Skin cancer is a major public health issue in Australia, with the treatment of non-melanoma skin cancer costing our community more than $264 million each year. Moreover, brain tumours remain the most common cause of cancer-related death in children and of these, medulloblastoma is the most commonly diagnosed. Our laboratory has made great progress in understanding the genetic pathways behind the most common form of skin cancer in Australia, Basal Cell Carcinoma (BCC), and medulloblastoma, a type of brain tumour that occurs predominantly in children. Having mapped and isolated the Naevoid Basel Cell Carcinoma Syndrome (NBCCS) gene called Patched, which is the driver for a medical condition where affected individuals have a predisposition for developing BCC and medulloblastoma, we were able to identify the Patched gene as a controller of a molecular signalling pathway called the Hedgehog pathway. The Hedgehog pathway is a set of genetic mutations that contribute to the development of a wide range of tumour types, including lung, pancreatic and ovarian cancer. By examining this pathway and how it interacts with other genetic pathways, our scientists have gained a better understanding of the normal development of the skin and cerebellum, a part of the brain that controls motor functions. By manipulating the strength of the Hedgehog pathway we believe stem cell populations can be expanded or can be induced to become cancerous. Our lab has identified the core genetic components that lead to the development of medulloblastoma. This work will enable the therapeutic targeting of every medulloblastoma, not just a subset, leading to more powerful clinical trials and ultimately more effective treatment options.

[2026] The SHH/GLI target Netrin-1 supports self-renewal in medulloblastoma tumor cells [2025] Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival [2025] Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target [2025] Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179 [2024] Germline ELP1 deficiency sensitizes cerebellar granule neuron progenitors to SHH medulloblastoma [2024] The virtual child [2024] “If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials [2023] Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumors [2023] Efficient